论文部分内容阅读
西比灵是一种新型选择性钙通道阻滞剂，与丹参进行对照研究。经CT证实急性缺血性中风80例，随机分成治疗组和对照组各40例。两组在性别、年龄、神经功能缺损的比较均无显著差异（P＞O．01和P＞0．1），研究具有可比性。经治疗观察，两组在双眼水平凝视、下肢肌力恢复有显著差异（P＜0．05）。言语、肩部、手肌力、步行、神经功能积分减少的平均值以及疗效评定，两组均有非常显著差异（p＜0．01），治疗组明显优于对照组。西比灵能通过血脑屏障，使脑血管扩张，改善红细胞的变形性和血粘度，使破坏的脑细胞得以再生，体征明显好转。该药使用方便，副作用小，值得推广应用。
Sibelium is a new selective calcium channel blocker, and Salvia control study. 80 cases of acute ischemic stroke confirmed by CT, were randomly divided into treatment group and control group of 40 cases. The two groups in gender, age, neurological deficit comparison showed no significant difference (P> O.01 and P> 0.1), the study is comparable. After treatment, there was a significant difference (P <0.05) between the two groups in staring at both eyes and muscle strength recovery of lower limbs. Speech, shoulder, hand muscle strength, walking, reduction of neurological function points and curative effect evaluation were significantly different between the two groups (p <0.01). The treatment group was significantly better than the control group. Xibeilin can pass through the blood-brain barrier, make the blood vessels dilate, improve the deformability and blood viscosity of erythrocytes, regenerate the destroyed brain cells, and the signs are obviously improved. The drug easy to use, side effects, it is worth promoting the application.